Sign In
Buy RIGL
$30.30
+0.280 (+0.93%)
At Close: Jun 03, 2026
Rigel (RIGL) Up on FDA Nod to Blood Cancer Drug Rezlidhia
02:18pm, Friday, 02'nd Dec 2022
The FDA approves Rigel's (RIGL) Rezlidhia (olutasidenib) for treating relapsed/refractory acute myeloid leukemia with a susceptible IDH1 mutation. Stock up.
Rigel Pharmaceuticals (RIGL) Stock Soars on FDA Approval News
11:17am, Friday, 02'nd Dec 2022
Rigel Pharmaceuticals (NASDAQ: RIGL ) stock is heading higher on Friday after getting approval from the U.S. Food and Drug Administration (FDA) for its leukemia treatment. Specifically, the FDA has ap
Rigel stock soars after FDA approves leukemia treatment, 2 days after receiving delisting notice
06:37am, Friday, 02'nd Dec 2022
Shares of Rigel Pharmaceuticals Inc. RIGL, +1.86% soared 39.5% in premarket trading Friday, after the biotechnology company announced Food and Drug Administration approval of its Rezlidhia leukemia tr
Rigel Pharmaceuticals (RIGL) Reports Q3 Loss, Lags Revenue Estimates
07:35pm, Thursday, 03'rd Nov 2022
Rigel (RIGL) delivered earnings and revenue surprises of 15.38% and 1.56%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Rigel Pharmaceuticals, Inc. (RIGL) Q3 2022 Earnings Call Transcript
07:25pm, Thursday, 03'rd Nov 2022
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 AM ET Company Participants Dolly Vance - Senior Advisor, Legal & Corporate Affairs Raul Rodriguez - Pr
Rigel Pharmaceuticals Provides An Opportunity For Investors Or An Acquirer
06:00pm, Monday, 31'st Oct 2022
RIGL hoped to expand the label of its drug Tavalisse (fostamatinib), but the failure of the drug in phase 3 appeared to scupper its chances. RIGL sought guidance to see if a reanalysis of the failed p
Rigel (RIGL) to Not Pursue the WAIHA Program, Cut Jobs
12:47pm, Tuesday, 11'th Oct 2022
Rigel (RIGL) decides to back out from the label expansion of fostamatinib for the treatment of patients with warm autoimmune hemolytic anemia (wAIHA) following the FDA???s review.
Piper Sandler Maintains Neutral Rating for Rigel Pharmaceuticals: Here's What You Need To Know
04:28pm, Wednesday, 17'th Aug 2022 Benzinga
Piper Sandler has decided to maintain its Neutral rating of Rigel Pharmaceuticals (NASDAQ:RIGL) and raise its price target from $1.00 to $2.00.
Shares of Rigel Pharmaceuticals are trading up 1.12% ove
Expert Ratings for Rigel Pharmaceuticals
12:24pm, Wednesday, 17'th Aug 2022 Benzinga
Rigel Pharmaceuticals (NASDAQ:RIGL) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
1
1
3
0
0
Rigel Pharmaceuticals, Inc. (RIGL) CEO Raul Rodriguez on Q2 2022 Results - Earnings Call Transcript
01:06am, Wednesday, 03'rd Aug 2022
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL ) Q2 2022 Earnings Conference Call August 2, 2022 4:30 PM ET Company Participants Dolly Vance - Executive Vice President, Corporate Affairs and General Counsel
Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue Estimates
10:05pm, Tuesday, 02'nd Aug 2022 Zacks Investment Research
Rigel (RIGL) delivered earnings and revenue surprises of 33.33% and 26.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue Estimates
07:36pm, Tuesday, 02'nd Aug 2022
Rigel (RIGL) delivered earnings and revenue surprises of 33.33% and 26.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
This Healthcare Stock Jumps Around 188%, Here's 83 Biggest Movers From Yesterday
08:23am, Tuesday, 28'th Jun 2022 Benzinga
Gainers
Evofem Biosciences, Inc. (NASDAQ: EVFM) shares jumped 187.7% to close at $1.07 on Monday amid the Supreme Court overturning Roe V Wade.
Acutus Medical, Inc. (NASDAQ: AFIB) climbed 87.6% to cl
Mosaic Tumbles Around 10%, Here's 71 Biggest Movers From Yesterday
09:35am, Friday, 24'th Jun 2022 Benzinga
Gainers
Fujian Blue Hat Interactive Entertainment Technology Ltd. (NASDAQ: BHAT) shares jumped 263% to $2.73 on Thursday. Blue Hat Interactive terminated its previously proposed shelf takedown offer
Biotech Penny Stocks Investing Guide
08:47pm, Monday, 20'th Jun 2022 PennyStocks
What to know about trading biotech stocks in 2022
The post Biotech Penny Stocks Investing Guide appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
